Retinoids

Journal of the American Academy of Dermatology

Volumn 50, Issue 3, 2004, Pages 405-415

  Sekula Gibbs, Shelley ^a   Uptmore, David ^b   Otillar, Laura ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Richmond Mental Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALITRETINOIN; ALPHA2A INTERFERON; BENZOYL PEROXIDE; BEXAROTENE; CORTICOSTEROID; ERYTHROMYCIN; ETRETIN; ETRETINATE; FLUOROURACIL; HYDROXYCHLOROQUINE; ISOTRETINOIN; RETINOIC ACID; RETINOID; TACROLIMUS; TAZAROTENE;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BIRTH DEFECT; BONE DISEASE; BRAIN PSEUDOTUMOR; CALCIFICATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CONGENITAL HEART MALFORMATION; CONJUNCTIVITIS; CORNEA ULCER; CRANIOFACIAL MALFORMATION; CUTANEOUS T CELL LYMPHOMA; DARIER DISEASE; DEPRESSION; DISCOID LUPUS ERYTHEMATOSUS; DRUG HYPERSENSITIVITY; DRUG INDICATION; EAR MALFORMATION; EYE MALFORMATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GRANULOMA; HAIR DISEASE; HEADACHE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; ICHTHYOSIS; INTRAHEPATIC CHOLESTASIS; KERATITIS; KERATOSIS PALMOPLANTARIS; LIVER DYSFUNCTION; MYALGIA; NAIL DISEASE; NEUROBLASTOMA; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN ATROPHY; SKIN IRRITATION; SKIN LUPUS ERYTHEMATOSUS; SKIN TOXICITY; SPONTANEOUS ABORTION; SQUAMOUS CELL CARCINOMA; SUICIDAL BEHAVIOR; TERATOGENICITY;

EID: 1542284068     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.08.001     Document Type: Review

References (82)

1. Savin RC, Berger RS. Split-face comparison of tretinoin cream .025% and adapalene gel .1% in the treatment of acne vulgaris. Cosmet Dermatol 1999;12(2):29-32.
2. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002;69:4-11.
3. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: A double-blind randomized trial. Cutis 2002:69;12-9.
4. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002:69:20-9.
5. Lehucher-Ceyrac D, La Salmoniere P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: 237 patients. Dermatol 1999;198:278-83.
6. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001;45:196-207.
7. Mengesha YM, Hansen RC. Toddler-age nodulocystic acne. J Pediatr 1999;134:644-8.
8. Jeffes E, Tang E. Actinic keratosis: Current treatment options. Am J Clin Dermatol 2000;1:167-79.
9. Peris K, Fargnoli M, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999;341:1767-8.
10. Duvic M, Bharati H, Schulz C, Cho M, DiSepio D, Hager C, et al. Expression of a retinoid-inducible tumor suppressor, tazarotene-inducible gene-3 is decreased in psoriasis and skin cancer. Clin Cancer Res 2000;6:3249-59.
11. Meyskens Jr FL, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 1986;15:822-5.
12. Halpern AC, Schuchter LM, Elder DE, Guerry IV D, Elenitsas R, Trock B, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994;12:1028-35.
13. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17.
14. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13- cis -retinoic acid and interferon α-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer 1992;84:235-41.
15. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60.
16. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-37.
17. Sanchez-Conejo-Mir J, Camacho F. Nevoid basal cell carcinoma syndrome: Combined etretinate and surgical treatment. J Dermatol Surg Oncol 1989;15:868-71.
18. Clayton BD, Jorizzo JL, Hitchcock MG, Fleischer Jr AB, Williford PM, Feldman SR, et al. Adult pityriasis rubra pilaris: A 10-year case series. J Am Acad Dermatol 1997;36:959-64.
19. DiGiovanna JJ. Systemic retinoid therapy. Dermatol Clin 2001;19:161-7.
20. Lundgren T, Crossner CG, Twetman S, Ullbro C. Systemic retinoid medication and periodontal health in patients with Papillon-Lefevre syndrome. J Clin Periodontol 1996;23:176-9.
21. Peck GL, Yoder FW. Treatment of lamellar ichthyosis and other keratinising dermatoses with an oral synthetic retinoid. Lancet 1976;2:1172-4.
22. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002;47:386-9.
23. English JC, Browne J, Halbach DP. Effective treatment of localized Darier's disease with adapalene 0.1% gel. Cutis 1999;63:227-30.
24. Reynolds CP, Lemmons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910.
25. McMichael AJ, Griffiths CE, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996;135:60-4.
26. Newton RC, Jorizzo JL, Solomon Jr AR, Sanchez RL, Daniels JC, Bell JD, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986;122:170-6.
27. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991;24:49-52.
28. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxycloroquine. Br J Dermatol 1992;127:513-8.
29. Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999;41:1049-50.
30. Duvic M, Martin AG, Kim Y, Olsen E, Wood G, Crowley C, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137: 581-93.
31. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Int Med 1987;147:529-31.
32. Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: A comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Dermato-Venereologica 1987;67:232-6.
33. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
34. Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Results of an open, pilot trial. Arch Dermatol 1995;131:1047-50.
35. Guerriero C, De Simone C, Guidi B, Rotoli M, Venier A. Follicular mucinosis successfully treated with isotretinoin. Eur J Dermatol 1999;9:22-4.
36. Boer J, Van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999;40:73-6.
37. Duvic M, Friedman-Kien A, Looney D, Miles S, Myskowski P, Scadden D, et al. Topical treatment of cutaneous lesions of acquired immune deficiency syndrome-related Kaposi sarcoma using alitretinoin gel. Arch Dermatol 2000;136:1461-9.
38. Walmsley S, Northfelt D, Melosky B, Conant M, Friedman-Kien A, Wagner B, et al. Treatment of AIDS-related Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr 1999;22:235-46.
39. Saiag P, Pavlovic M, Clerici T, Feauveau V, Nicolas JC, Emilie D, et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: Results of a sequential non-randomized phase II trial. AIDS 1999;12:2169-76.
40. Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol 1986;62:393-6.
41. Cribier B, Frances C, Chosidow O. Treatment of lichen planus: An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521-30.
42. Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985;35:390-1.
43. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 1993;129:415-21.
44. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993;328:1438-43.
45. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
46. Ellis CN, Weiss JS, Hamilton TA, Headington JT, Zelickson AS, Voorhees JJ. Sustained improvement with prolonged topical tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol 1990;24:629-37.
47. Griffiths CE. The role of retinoids in the prevention and repair of aged and photoaged skin. Clin Exp Dermatol 2001;26:613-8.
48. Maddin S, Lauharanta J, Agache P, Burrows L, Zultak M, Bulger L. Isotretinoin improves the appearance of photo-damaged skin: Results of a 36-week, multicenter, double blind, placebo-controlled trial. J Am Acad Dermatol 2000;42:56-63.
49. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. JAMA 1988;259:527-32.
50. Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of ultraviolet or chemically induced oxidative stress. Skin Pharmacol Appl Skin Physiol 2001;14:363-72.
51. Tran C, Sorg O, Carraux P, Didierjean L, Saurat JH. Topical delivery of retinoids counteracts the UVB-induced epidermal vitamin A depletion in hairless mouse. Photochem Photobiol 2001;73:425-31.
52. Wang Z, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med 1999;5:849.
53. Pirard GE, Kligman AM, Stoudemayer T, Leveque JL. Comparative effects of retinoic acid, glycolic acid and a lipophilic derivative of salicylic acid on photodamaged epidermis. Dermatology 1999;199:50-3.
54. Olsen EA, Katz HI, Levine N, Nigra TP, Poci PE, Savin RC, et al. Sustained improvement in photodamaged skin with reduced tretinoin emollient cream treatment regimen: effect of once-weekly and three-times-weekly applications. J Am Acad Dermatol 1997;37:227-30.
55. Fujii K, Kanno Y, Konishi K, Ohgou N. Short-term etretinate therapy for prurigo chronica multiformis. J Dermatol 2002;29:146-51.
56. Saurat JH. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999;41(Suppl):S2-S6.
57. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb A, Zanolli M. Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53.
58. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
59. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene(Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002;46:907-13.
60. Koo JY, Lowe NJ, Lew-Kaya DA,Vasilopoulos AI, Lue JC, Sefton J, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000;43:821-8.
61. Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002;47:969-70.
62. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998;134:884-5.
63. Thiboutot DM. Acne and rosacea. New and emerging therapies. Dermatol Clin 2000;18:63-71.
64. Georgiou S, Monastirli A, Pasmatzi E, Tsamboas D. Cutaneous sarcoidosis: Complete remission after oral isotretinoin therapy. Acta Derm Venereol 1998;78:457-9.
65. Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidiosis with isotretinoin. Arch Dermatol 1983;119:1003-5.
66. Rangel O, Arias I, Garcia E, Lopez-Padilla S. Topical tretinoin 0.1% for pregnancy-related abdominal striae: An open-label, multicenter, prospective study. Adv Ther 2001;18:181-6.
67. Kang S, Kim KJ, Griffiths CE, Wong TY, Talwar HS, Fisher GJ, et al. Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol 1996;132:519-26.
68. Pribanich S, Simpson FG, Held B, Yarbrough CL, White SN. Low-dose tretinoin does not improve striae distensae: A double blind, placebo-controlled study. Cutis 1994;54:121-4.
69. Grimalt R, Ferrando J, Mascaro J. Premature familial sebaceous hyperplasia: Successful response to oral isotretinoin in three patients. J Am Acad Dermatol 1997;37:996-8.
70. Cardamakis EK, Kotoulas IG, Dimopoulos DP, Stathopoulos EN, Michopoulos JT, Tzingounis VA. Comparative study of systemic interferon alfa-2a with oral isotretinoin alone in the treatment of recurrent condylomata accuminata. Arch Gynecol Obstet 1996;258:35-41.
71. Stone SP. Unusual, innovative and long-forgotten remedies. Dermatol Clin 2000;18:323-38.
72. Pauquett D, Badiavas E, Falanga V. Short-contact topical tretinoin therapy to stimulate granulation tissue in chronic wounds. J Am Acad Dermatol 2001;45:382-6.
73. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001;45:S150-S157.
74. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis. J Am Acad Dermatol 1999;41:S7-S12.
75. Strauss JS, Gottlieb AB, Jones T, Koo JY, Leyden JJ, Lucky A, et al. Concomitant administration of vitamen E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. J Am Acad Dermatol 2000;43:777-84.
76. Leyden J, Grove GL. Randomized facial tolerability studies comparing gel formulations of retinoids used to treat acne vulgaris. Cutis 2001;67:17-27.
77. S.M.A.R.T. ProgramFDA/Roche Laboratories collaboration. January 2002. http://www.fda.gov/cder/drug/infopage/accutane/smart.pdf : 1-76.
78. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression and isotretinoin is there a causal link? J Am Acad Dermatol 2001;45:S168-75.
79. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000;136:1231-6.
80. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001;45:515-9.
81. Brisaert M, Plaizier-Vercammen J. Investigation on the photostability of a tretinoin lotion and stabilization with additives. Int J Pharm 2000;199:49-57.
82. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet light. Br J Dermatol 1998;139(Suppl 52):8-11.